(UroToday.com) Docetaxel chemotherapy is a standard of care treatment option in metastatic castration-resistant prostate cancer (mCRPC). Docetaxel intravenous infusion is associated with infusion reactions that require the administration of prophylactic steroids, which can cause undesired side effects especially in patients with baseline glucose intolerance or metabolic syndrome. ModraDoc006 is an oral tablet formulation of docetaxel that is administered with ritonavir (to inhibit P-glycoprotein and CYP3A4) to increase bioavailability. A prior phase 1b study suggested the safety and preliminary efficacy of this drug. In this abstract, Ulka Vaishampayan presents results from M18MDP, an ongoing multicenter phase 2b study evaluating the efficacy of ModraDoc006 in mCRPC patients who are suitable for taxane treatment. The study schema is shown below.